TNDM
Tandem Diabetes Care Inc

14,026
Loading...
Loading...
News
all
press releases
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up
Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Tandem Diabetes Care (TNDM) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·1mo ago
News Placeholder
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Beats Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -20.00% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
Zacks·1mo ago
News Placeholder
Bears are Losing Control Over Tandem Diabetes Care (TNDM), Here's Why It's a 'Buy' Now
Tandem Diabetes Care (TNDM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks·1mo ago
News Placeholder
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of -87.50% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know
Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy?
Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM)
The heavy selling pressure might have exhausted for Tandem Diabetes Care (TNDM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·2mo ago
News Placeholder
Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes
Investing.com -- Citi analysts have taken action on two U.S. MedTech names, upgrading Haemonetics (NYSE:HAE) to Buy from Neutral, while downgrading Tandem Diabetes Care (NASDAQ:TNDM) to Sell/High Risk from Neutral/High Risk, citing diverging prospects in the second half of 2025.
investing.com·2mo ago

Latest TNDM News

View

Advertisement. Remove ads.

Advertisement. Remove ads.